{"id":17859,"date":"2022-10-24T15:31:19","date_gmt":"2022-10-24T15:31:19","guid":{"rendered":"https:\/\/globalhealthintelligence.com\/?p=17859"},"modified":"2025-12-01T14:56:33","modified_gmt":"2025-12-01T20:56:33","slug":"the-pandemic-is-part-of-our-evolution","status":"publish","type":"post","link":"https:\/\/globalhealthintelligence.com\/ghi-analysis\/the-pandemic-is-part-of-our-evolution\/","title":{"rendered":"The Pandemic is Part of Our Evolution"},"content":{"rendered":"\n
\"William<\/figure><\/div>\n\n\n\n

Interview with William Krinickas<\/strong>
Vice President for Latin America
MicroPort<\/p>\n\n\n\n

<\/div>\n\n\n\n

In a chat\nwith William Krinickas, MicroPort\u2019s Latin America chief, we discussed the\nimpact of the pandemic on the health sector and the new opportunities that have\nappeared in the market.<\/p>\n\n\n\n

Latin America is a long way from achieving a health system\ncomparable to other regions. What do you think the causes might be?<\/strong><\/strong><\/p>\n\n\n\n

The issue\ncontinues to be limited patient access to therapies for a variety of reasons.\nOne of the main obstacles to better health systems and the efficient use of\nresources in some countries of the region has been corruption, which generates\ninstability and profound economic crises within each ecosystem.<\/p>\n\n\n\n

On the other hand, we live in a context where there is a constant lack of legal certainty, affecting the ability to plan for the long term. This generates mistrust and low predictability throughout the region as it is very hard to achieve economic stability without political stability.  Add to this the negative growth rates in recent years.<\/p>\n\n\n\n

\"Arterial
The first implantation of MicroPort\u2019s APOLLO<\/a>\u2122 intracranial stent in Brazil was in August 2022<\/em><\/figcaption><\/figure>\n\n\n\n

The\npandemic has highlighted the strengths and weaknesses of health systems in the\nregion, as well as the consequences of corruption that we have lived through in\nseveral of the region\u2019s markets. This is Latin America\u2019s cancer.<\/p>\n\n\n\n

Conversely,\nour pricing is shifting more and more toward greater transparency, which will\nallow us to improve access by democratizing the scope of devices and equipment\nthat used to be unfeasible for our region. This is possible because of the\ncollaboration between the industry\u2019s businesses and associations and our\ngovernments, with a view to moving forward.<\/p>\n\n\n\n

The pandemic is not over yet, although it appears to be in\nits final stage. How do you think this has affected the health sector, and what\nlessons has the industry learned in this regard?<\/strong><\/strong><\/p>\n\n\n\n

The\npandemic has caused chaos in our societies and created long-term disruptions to\nour health systems. All the procedures or checks that used to be done but have\nstopped being done will be reflected in clinical cases over the next few years,\nand this situation will have a big impact within the health system. We are\nexperiencing something that is unprecedented, a phenomenon that is beyond our\ngrasp.  <\/p>\n\n\n\n

Personally,\nI don\u2019t think it has only had a negative impact. COVID-19 has also changed our\napproach and has opened the door to new opportunities: for example, among the\nmost prominent [events] is the fact that telemedicine has assumed a leading\nrole, [there has been] a redistribution of budgets, and a rearrangement of the\nsystem to achieve better patient care or greater coverage. I believe these\nshould be what our interests are as an industry, as governments, and as a\nmedical community. We have a duty to take care of the population\u2019s health, and\ncurrently many companies are participating in green or sustainable economy\nprograms, which is the future of health.<\/p>\n\n\n\n

The last few years have been a time\nof crisis for some companies, and of opportunities for others. How did\nMicroPort fare?<\/strong><\/strong><\/p>\n\n\n\n

The\npressures of the pandemic have been enormous for all countries and their\nrespective industries. The crisis brought about by COVID-19 has considerably\ndepleted the budgets. These structural changes have given new developers the\nchance to enter the medical-device market, offering quality products at more\naffordable prices for healthcare systems whose budgets have been significantly\naffected.<\/p>\n\n\n\n

The\ncapacities of healthcare systems have changed completely to be able to continue\nproviding coverage in terms of both quantity and quality. This situation has\ngiven rise to new offers of value, technology, and quality, such as minimally\ninvasive procedures.<\/p>\n\n\n\n

For\nMicroPort, the pandemic has been a moment of opportunity; we have been able to\nadd our portfolio of medical and robotic devices to most areas of minimally\ninvasive therapy. These types of surgery have significant benefits over\ntraditional surgery. Physicians have greater control of the procedure [by]\nmaking small, precise incisions without trembling hands, as they can operate\nwith mechanical movements, made by the robot. [This means] they can easily get\nto hard-to-reach areas, with significantly better vision thanks to the\nequipment\u2019s built-in cameras. For the patient, this means faster recovery times\nthan in traditional operations, with less blood loss, fewer complications, and\nsmaller scars. In all cases, these types of surgery are more beneficial.<\/p>\n\n\n\n

\u2014———————<\/p>\n\n\n\n

MicroPort\nis a multinational that has been developing and manufacturing medical devices\nfor the whole world for more than 20 years. It is one of the top 100\nmedical-device companies.<\/p>\n","protected":false},"excerpt":{"rendered":"

Interview with William Krinickas, Vice President for Latin America, MicroPort<\/p>\n","protected":false},"author":24,"featured_media":17860,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32],"tags":[],"class_list":{"0":"post-17859","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ghi-analysis"},"_links":{"self":[{"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/posts\/17859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/comments?post=17859"}],"version-history":[{"count":1,"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/posts\/17859\/revisions"}],"predecessor-version":[{"id":28699,"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/posts\/17859\/revisions\/28699"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/media\/17860"}],"wp:attachment":[{"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/media?parent=17859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/categories?post=17859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/globalhealthintelligence.com\/wp-json\/wp\/v2\/tags?post=17859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}